0001209191-19-018232.txt : 20190308
0001209191-19-018232.hdr.sgml : 20190308
20190308175115
ACCESSION NUMBER: 0001209191-19-018232
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190307
FILED AS OF DATE: 20190308
DATE AS OF CHANGE: 20190308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Currie Mark G
CENTRAL INDEX KEY: 0001478244
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 19670276
MAIL ADDRESS:
STREET 1: C/O IRONWOOD PHARMACEUTICALS INC
STREET 2: 320 BENT STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-07
0
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001478244
Currie Mark G
C/O IRONWOOD PHARMACEUTICALS, INC.
301 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Scientific Officer
Class A Common Stock
2019-03-07
4
S
0
225500
13.29
D
577980
D
Class A Common Stock
2019-03-08
4
S
0
49500
13.15
D
528480
D
Mark Currie sold the shares of common stock of Ironwood Pharmaceuticals, Inc. to raise proceeds to fund a portion of his commitment to purchase shares of common stock of Cyclerion Therapeutics, Inc. alongside other investors in a private placement.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.94 to $13.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Conor Kilroy, Attorney-in-Fact
2019-03-08